NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
27/06/2026
Voltar para busca
Dado oficial do USPTO
NANO-OJAS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
21/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
16/06/2016
Data de registro
20/12/2016
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
27/06/2026
Última transação
21/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Primeiro uso
21/05/2014
Primeiro uso no comércio
21/05/2014
Código do desenho
4
Tipo de titular
03
Localização do titular
Chappaqua, NY, US
Examinador
KUNG, KAELIE ELIZABETH
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
NANORX INC.
Representantes
Scott D. Locke Dorf Nelson & Zauderer LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Analgesic and muscle relaxant nutraceutical preparations; Anti-diabetic nutraceuticals; Cardiovascular nutraceuticals; Nutraceutical preparations for the treatment of gout; Nutraceutical preparations and substances for the treatment of gastro-intestinal diseases; Nutraceutical preparations and substances for the treatment of infectious diseasesblood disorderspaininflammationsepsisalopeciaobesity and cognitive disorders; Nutraceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Nutraceutical preparations for inhalation for the treatment of pulmonary hypertension; Nutraceutical preparations for the prevention and treatment of disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary system; Nutraceutical preparations for the treatment of inflammatory disorders; Nutraceutical preparations for use in dermatologyoncologyhematology and in tissue and organ transplantationin ophthalmology and for gastroenterological disorders; Nutraceutical preparations for the prevention and treatment of ocular disorders or diseasesbacteria-based diseases or disordersautoimmune diseases or disorderskidney diseases or disordersdiabetes; Nutraceutical preparations for the prevention of diabetes; Nutraceutical preparations for the treatment of eye diseases and conditions; Nutraceutical preparations for the treatment of heart rhythm disorders; Nutraceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Nutraceutical preparations for the treatment of infectious diseases; Nutraceutical preparations for the treatment of hypertension; Nutraceutical preparations for treating allergic rhinitis and asthma; Nutraceutical preparations for treating diabetes; Nutraceutical preparations for treating skin disorders; Nutraceutical preparations for use in urology; Nutraceutical preparationsa blood clotting aid and delivery system for use in human and veterinary medicine; Nutraceutical products for ophthalmological use; Nutraceutical products for the treatment of bone diseases; Nutraceutical products for the treatment of joint disease; Nutraceutical products for the treatment of viral and infectious diseases; Nutraceutical preparations for the treatment of cancer; Nutraceutical products for treating respiratory diseases and asthma; Nutraceutical solutions used in dialysis; Nutraceuticalslipid lowering agents; Plant extracts for medicalveterinary and nutraceutical purposes; Therapeutic nutraceuticals for the treatment of obesity
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
27/06/2026
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
27/06/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
27/06/2026
E89R
TEAS SECTION 8 & 9 RECEIVED
27/04/2026
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
20/12/2025
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
18/05/2023
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
18/05/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
18/05/2023
E815
TEAS SECTION 8 & 15 RECEIVED
03/11/2022
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
20/12/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
20/12/2016
CHPB
POST PUBLICATION AMENDMENT - ENTERED
05/10/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/10/2016
PUBO
PUBLISHED FOR OPPOSITION
04/10/2016
DOCK
ASSIGNED TO EXAMINER
04/10/2016
APET
ASSIGNED TO PETITION STAFF
27/09/2016
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
15/09/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
14/09/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
30/08/2016
ALIE
ASSIGNED TO LIE
30/08/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
15/08/2016
XAEC
EXAMINER'S AMENDMENT ENTERED
15/08/2016
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
15/08/2016
GNEA
EXAMINERS AMENDMENT E-MAILED
15/08/2016
CNEA
EXAMINERS AMENDMENT -WRITTEN
15/08/2016
DOCK
ASSIGNED TO EXAMINER
15/08/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
22/06/2016
NWAP
NEW APPLICATION ENTERED
20/06/2016
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace NANO-OJAS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.